LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Lista de Ações・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Fechado

SetorSaúde

23.38 -1.18

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

23.22

Máximo

23.45

Indicadores-chave
By Trading Economics
Rendimento	-56M -185M
Vendas	-71M 136M
EPS	-1.541
Margem de lucro	-136.029
Funcionários	1,371
EBITDA	-56M -161M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+121.76% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-57M 2.4B
Abertura anterior	24.56
Fecho anterior	23.38

Sentimento de Notícias

By Acuity

100%

63 / 345 Ranking em Healthcare

Ultragenyx Pharmaceutical Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de mai. de 2026, 16:33 UTC

Ganhos

Grandes Movimentos do Mercado

Webull Shares Slide on 1Q Loss, Soaring Costs

23 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

23 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 de mai. de 2026, 08:00 UTC

Ganhos

AI Could Kill the Brokerage Industry's Cash Cow -- Barrons.com

23 de mai. de 2026, 05:58 UTC

Ganhos

Our Cadre Holdings Pick Has Disappointed. We're Sticking With It. -- Barrons.com

22 de mai. de 2026, 21:10 UTC

Ganhos

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2026, 19:47 UTC

Ganhos

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 de mai. de 2026, 19:17 UTC

Conversa de Mercado

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 de mai. de 2026, 19:10 UTC

Conversa de Mercado

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de mai. de 2026, 18:54 UTC

Conversa de Mercado

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 de mai. de 2026, 18:38 UTC

Conversa de Mercado

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 de mai. de 2026, 18:35 UTC

Aquisições, Fusões, Aquisições de Empresas

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 de mai. de 2026, 18:09 UTC

Conversa de Mercado

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 de mai. de 2026, 17:58 UTC

Conversa de Mercado

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 de mai. de 2026, 17:54 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

22 de mai. de 2026, 17:54 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 de mai. de 2026, 17:54 UTC

Conversa de Mercado

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 de mai. de 2026, 17:03 UTC

Conversa de Mercado

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 de mai. de 2026, 16:54 UTC

Conversa de Mercado

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

22 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

22 de mai. de 2026, 16:16 UTC

Conversa de Mercado

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Ultragenyx Pharmaceutical Inc Previsão

Preço-alvo

By TipRanks

121.76% parte superior

Previsão para 12 meses

Média 51.87 USD 121.76%

Máximo 96 USD

Mínimo 25 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para Ultragenyx Pharmaceutical Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

16 ratings

Comprar

Manter

Vender

Com base em 16 analistas que deram avaliações de ações para Ultragenyx Pharmaceutical Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

63 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.